Agenus Unternehmenskultur

Mr. Ozer Baysal has been Chief Commercial Officer & Head of HR at Agenus Inc., since July 1, 2017. Mr. Baysal served as the Chief Business Officer of Agenus Inc. since January 2013 until July 1, 2017. Mr. Baysal leads Agenus' efforts in establishing commercial capability and accelerating Agenus' transition to becoming a fully integrated biopharmaceutical company. Previously, he spent 30 plus years with Pfizer in a broad number of functional and geographic areas, where he served as President of Europe, Emerging Markets Region where he grew revenue to $2.5 billon. He has held key leadership positions in Marketing, Sales, Manufacturing, Country Management and Corporate. While at Pfizer, he successfully integrated three major acquisitions and was actively involved with numerous licensing and M&A activites. He holds a bachelor's degree from Bosphorus University in Industrial Engineering and has completed the Programs for Leadership and Management Development at Harvard Business School.

Dr. Robert B. Stein, also known as Bob, Ph.D., M.D. has been Senior R&D Advisor at Agenus Inc. since April 1, 2017 an served as its President of Research and Development from September 2015 to April 1, 2017. Dr. Stein serves as scientific adviser to Takeda Pharmaceutical Co. Ltd. Dr. Stein has over 30 years of experience and accomplishments to the Agenus leadership team. He is an innovative and experienced executive with deep, broad knowledge of biology, medicine and pharmaceutical science. Dr. Stein lead Agenus' Research, Pre-clinical Development and Translational Medicine functions and guide the company's clinical development. In addition, pending closing, Dr. Stein play a critical role in leading the integration of the 4-Antibody acquisition announced today, which includes the company's fully human antibody drug discovery and optimization technology platform and portfolio of immune checkpoint antibody programs. Dr. Stein served as the Chief Executive Officer of KineMed, Inc. since August 01, 2008. Dr. Stein served as President of Roche Palo Alto from 2003 to 2006. Dr. Stein served as President and Chief Scientific Officer of Incyte Corporation since November 2001 until August 22, 2003. He served as Chief Scientific Officer at Agenus Inc. since February 2014 until January 27, 2016. Dr. Stein served as Executive Vice President of Research and Preclinical Development of DuPont Pharmaceuticals Company, formerly The DuPont Merck Pharmaceutical Company, from 1990 to November 2001. Dr. Stein has over 25 years of experience in research and development and business roles with pharmaceutical and biotechnology companies. He served as Executive Vice President of Research and Pre-clinical Development from 1990 to 1996. Dr. Stein served as Senior Vice President and Chief Scientific Officer from May 1990 to September 1996 and Vice President of Research and Preclinical Development from 1992 to 1993 and Vice President of Research for Ligand Pharmaceuticals, Inc. from 1990 to 1992. Dr. Stein spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He was Senior Vice President of Research for Ligand Pharmaceuticals. He held various positions with Merck & Co., Sharp & Dohme Research Laboratories from 1982 to 1990, which included Senior Director and Head of the Department of Pharmacology from 1989 to 1990. Dr. Stein serves on the President's Board of Advisors for Science and Innovation for the University of California. Dr. Stein has been Director of Archemix Corp. since April 03, 2007. He has been a Director of Atrinsic, Inc. since February 12, 2016. He serves as a Director of Incyte Genomics. He served as a Director of diaDexus, Inc. He served as a Director of KineMed, Inc. since August 1, 2008. He served as Director of Incyte Corporation from 2001 to August 21, 2003. He served as Director of Geron Corporation from April 1996 to September 2, 2003. He completed residency training and is board certified in anatomic and clinical pathology. Dr. Stein holds B.S. in Biology and Chemistry from Indiana University. He also holds M.D. and Ph.D. in Physiology and Pharmacology from Duke University.

Ms. Christine M. Klaskin has been the Vice President of Finance of Agenus Inc. (formerly, Antigenics Inc.) since July 2006 and served as its Principal Accounting Officer since October 2006 until September 26, 2017 and Principal Financial Officer since July 29, 2016 until September 26, 2017. Ms. Klaskin joined Agenus Inc. in 2000 and served in various finance positions. Ms. Klaskin previously served as the Principal Financial Officer of Agenus Inc. since May 2012. From 1987 to 1996, she served as an Audit Manager of Arthur Andersen LLP. She has been a Director of American DG Energy Inc. since January 20, 2012. Ms. Klaskin is a Certified Public Accountant and earned her Bachelor of Accountancy from The George Washington University.

Ms. Shalini Sharp has been Treasurer and Vice President of Dimension Therapeutics, Inc. since November 7, 2017. Ms. Sharp has been the Chief Financial Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc. since May 21, 2012 and January 2016 respectively. Ms. Sharp is responsible for leading the corporate finance, strategy and information technology functions and is a member of the Ultragenyx's executive leadership team. Ms. Sharp served as Senior Vice President of Ultragenyx Pharmaceutical Inc. from May 21, 2012 to January 2016 and served as its Principal Accounting Officer until March 24, 2014. Ms. Sharp served as Senior Vice President of Ultragenyx Pharmaceutical, Inc. since May 2012. She served as the Chief Financial Officer and Vice President of Antigenics Inc. from September 9, 2006 to May 2012. She served as the Chief Financial Officer and Vice President of Agenus Inc. from September 30, 2006 to May 11, 2012 and also served as its Senior Director of Strategic Planning and Corporate development. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. She served as Senior Director of Strategic Planning and Corporate Development of Antigenics Inc. Since 2003, In this position she managed strategic planning, investor relations and financing & acquisition transactions. Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as Chief of Staff to the Chairman of the Board of Directors during that its restructuring. Ms. Sharp served as Director of Strategic Planning at Elan Corporation Plc. She served as Management Consultant of McKinsey & Company, specializing in pharmaceuticals and medical devices. Ms. Sharp was an Investment Banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. She has been an Independent Director of Array BioPharma Inc. since April 27, 2017. She has been a Director of Agenus Inc. (Antigenics Inc.) since May 11, 2012. She serves as a Member of The Board of Directors of the TB Alliance. She has worked in investment banking at Goldman, Sachs & Company, primarily in the health care field. Ms. Sharp holds both a B.A., magna cum laude and a M.B.A. from Harvard University.

Ms. Karen Higgins Valentine, J.D. has been Chief Legal Officer of Antigenics Inc. since July 2015. Ms. Valentine has been a General Counsel of Antigenics Inc., since January 2008 and served as its Vice President from January 2008 to July 2015. She has been its Chief Compliance Officer since 2008. Ms. Valentine has been a Secretary of Antigenics Inc. since 2007 and served as its Assistant Secretary. She holds a BS in neuroscience from Colgate University, and received her law degree from Boston University School of Law.

Dr. Christian Cortis, also known as Chris, PhD, has been Chief Strategy Officer at Agenus Inc. since September 26, 2017. Dr. Cortis served as Vice President of Business Development at Agenus Inc. since January 27, 2016. Dr. Cortis served as Vice President of Strategic Alliances & External Resources at Agenus Inc. He was a Principal at Advanced Technology Ventures. He joined the firm in 2006 and focused on healthcare investments, specifically in the biotechnology, life science and diagnostic sectors. Dr. Cortis served as Executive at Booz Allen Hamilton Holding Corporation. He worked at Gemin X Biotechnologies in Canada as Senior Director of Business Development, where Dr. Cortis was responsible for sourcing, structuring and executing the company's acquisitions, partnerships and licensing activities. During his tenure, he completed twelve transactions including the in-licensing of GMX1777, Gemin X's second clinical-stage program and a company acquisition whose technology served as the foundation of a new discovery program. Dr. Cortis also worked as an Associate at International Real Returns LLC as the Member of the Venture Capital Team focused on biotechnology investment. He spent four years working in venture capital and biotechnology consulting, with Booz Allen & Hamilton. At Booz Allen & Hamilton, Dr. Cortis worked with biotechnology and pharmaceutical companies consulting on a range of projects from the commercialization of proteomics technology to designing global research and development programs, to outlining strategies for mergers and acquisitions. He serves as a Board Observer of Catabasis. Inc. He served as a Board Observer of Receptos, Inc Dr. Cortis was a post-doctoral fellow at Columbia University in the department of Biochemistry and Molecular Biophysics. He holds a Ph.D. degree in Applied Mathematics and Theoretical Chemistry from Columbia University and a B.Sc. degree from McGill University.

Dr. Michael Plater, Ph.D., has been Chief Business Officer at Agenus Inc. since September 26, 2017. Dr. Plater served as the Head of Corporate Affairs and Chief of Staff to the Chief Executive Officer at Agenus Inc. since July 25, 2017 until September 26, 2017. Dr. Plater oversees and leads strategic initiatives to accelerate the Agenus portfolio and oversees Agenus Corporate Communications and Investor Relations. He has 20 years of global pharmaceuticals experience in diverse leadership roles at both GlaxoSmithKline and Novartis. He served at GSK , where he completed substantial divestment, market access and licensing transactions across Asia-Pacific, Europe and the U.S., and managed U.S. government contracting. Dr. Plater obtained his PhD in Molecular Genetics and Protein Biochemistry from the Wolfson Laboratory, University Reading, U.K.

Dr. Alexander R. Duncan, also known as Alex, BSc, MA, Ph.D., has been Chief Technology Officer at Agenus Inc. since January 27, 2016 and its Head of Research since September 26, 2017. Dr. Duncan served as Vice President of Preclinical Development of Agenus Inc. since July 2015 until January 2016. Dr. Duncan served as Senior Vice President of Research and Development of Affitech AS since September 2009 and served as its Chief Scientific Officer and Member of Executive Board. Dr. Duncan is a leading antibody research scientist and business leader. He served as Senior Vice President Drug Discovery at MedImmune Limited. He served as Vice President - Drug Discovery of MedImmune Limited. Dr. Duncan served as Vice President and Senior Vice President of Drug Discovery of Cambridge Antibody Technology Group PLC. and has been with Cambridge Antibody Technology Group PLC since 1994. He led the Cambridge UK Discovery site, previously Cambridge Antibody Technology (CAT), through its integration with Medimmune. Dr. Duncan has been with CAT since 1994. He served as Vice President Drug Discovery, he held the position of Head of Antibody Engineering. At Astra Zeneca, he was a member of AZ Discovery senior management team and SVPBiopharmaceuticals. He served as Member of Scientific Advisory Board at MedImmune Limited. He served as a Director of ExpreS2ion Biotechnologies ApS. Before joining CAT, he was a Research Fellow at the University of California and prior to that, a Lucille P Markey Visiting Fellow also at the University of California. Dr. Duncan gained his PhD in Dr. Sir Greg Winter'slaboratory at the MRC Laboratory of Molecular Biology, University of Cambridgeand held post-doctoral positions at the University of California San Diego.

Christian Cortis serves as the Chief Strategy Officer and Head of Finance of Agenus (formerly Antigenics). Christian started at Agenus (formerly Antigenics) in June of 2018. Christian is currently based in the Greater Boston Area.